Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...
A virus originally found in animals, mpox -- which causes the disease of the same name -- is now circulating in humans. Since 2022, it has been the cause of major epidemics spreading outside endemic ...
Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...
Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the ...
A FaceTime "prank" using an old video sourced from Aurukun man Eric Yunkaporta's TikTok account — without his consent — has gone viral on social media, garnering millions of views. Eric's ...
Ethris Presents Positive Topline Phase 1 Data with mRNA Lead Candidate ETH47 for Uncontrolled Asthma
MUNICH, Germany I January 30, 2025 I Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced ...
During the COVID-19 pandemic, health worker Maria Tereza Malheiros Sapienza's curiosity was aroused by her immunity to SARS-CoV-2: her husband, Marcelo Sapienza, a physician, was infected twice (in ...
INNA-051 is a host defence immune enhancer which locally primes and boosts the body’s innate immune response – the natural first line of defence. It is being developed as a convenient, once-a-week ...
MELBOURNE, Australia, Jan. 28, 2025 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host ... and boosts the body’s innate immune response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback